# A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

> **NCT03616912** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 830 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03616912
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-02
- **Primary completion:** 2021-11-01
- **Final completion:** 2022-03-09
- **Target enrollment:** 830 (ACTUAL)
- **Why stopped:** Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients.
- **Last updated:** 2023-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616912, "A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03616912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*